Reaction

Transplant Dysfunction reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,738 reports · 54 co-occurring drugs

As of the last recalculation, Transplant Dysfunction appears in 1,738 FAERS reports alongside 54 co-occurring drug terms. The strongest observed disproportionality signal is TACROLIMUS (PRR 335.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Tacrolimus	1,248	335.9	338.6
Mycophenolate Mofetil Hydrochloride	1,031	221.6	223.3
Mycophenolate Mofetil	1,030	221.5	223.2
Tacrolimus Ointment 0.1%	891	174.8	176.0
Basiliximab	156	174.4	176.8
Tacrolimus Extended-Release Capsules	891	174.3	175.6
Valganciclovir Hydrochloride Powder,	111	116.4	117.4
Valganciclovir	141	97.4	98.1
Valganciclovir Hydrochloride	141	97.4	98.1
Cyclosporine	588	95.1	95.6
Mycophenolic Acid	172	71.3	71.7
Thiotepa	53	68.5	68.9
Anti-Thymocyte Globulin (Rabbit)	44	67.0	67.4
Mycophenilic Acid	103	63.2	63.5
Busulfan	70	55.5	55.7
Ganciclovir Sodium	43	49.9	50.1
Ganciclovir	41	49.1	49.3
Everolimus Tablets	42	30.7	30.8
Sulfasalazine	179	30.4	30.5
Sirolimus	32	29.0	29.0
Eltrombopag Olamine	54	28.9	29.0
Infliximab	407	28.8	28.9
Fludarabine Phosphate	80	25.5	25.5
Prednisolone	266	20.7	20.7
Prednisolone Oral	266	20.7	20.7
Prednisolone Oral Solution	266	20.7	20.7
Pyrazinamide	15	19.3	19.3
Terazosin Hydrochloride	13	17.6	17.7
Alemtuzumab	26	16.3	16.3
Indapamide	24	16.2	16.3
Etanercept	456	12.0	12.0
Rifampicin	10	11.9	11.9
Sevoflurane	8	11.6	11.6
Amphotericin B	12	11.5	11.6
Isoniazid	15	11.2	11.2
Temazepam	34	11.0	11.0
Entecavir	10	10.3	10.3
Everolimus	42	10.1	10.1
Voriconazole Injection	18	10.0	10.0
Itraconazole	9	9.3	9.3
Cyclophosphamide Injection, Solution	121	8.7	8.7
Cyclophosphamide	121	8.7	8.7
Cyclophosphamide For Injection	121	8.7	8.7
Daspone	7	8.6	8.6
Dapsone Gel, 5%	7	8.6	8.6
Micafungin Sodium	6	8.5	8.5
Voriconazole	20	8.0	8.0
Meropenem	21	7.9	7.9
Lamivudine Oral	16	7.6	7.6
Remdesivir	7	6.3	6.3
Blinatumomab	5	5.8	5.8
Linezolid	14	5.7	5.7
Sofosbuvir	8	4.9	4.9
Ranitidine Hydrochloride	11	2.4	2.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.